CN101675930B - 用于治疗增生性疾病的药物组合物 - Google Patents
用于治疗增生性疾病的药物组合物 Download PDFInfo
- Publication number
- CN101675930B CN101675930B CN2008101496507A CN200810149650A CN101675930B CN 101675930 B CN101675930 B CN 101675930B CN 2008101496507 A CN2008101496507 A CN 2008101496507A CN 200810149650 A CN200810149650 A CN 200810149650A CN 101675930 B CN101675930 B CN 101675930B
- Authority
- CN
- China
- Prior art keywords
- tumor
- administration
- purposes
- formula
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WPEWQEMJFLWMLV-UHFFFAOYSA-N N#CC1(CCCC1)c(cc1)ccc1NC(c1cccnc1NCc1ccncc1)=O Chemical compound N#CC1(CCCC1)c(cc1)ccc1NC(c1cccnc1NCc1ccncc1)=O WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (14)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101496507A CN101675930B (zh) | 2008-09-16 | 2008-09-16 | 用于治疗增生性疾病的药物组合物 |
PCT/CN2009/072238 WO2010031265A1 (zh) | 2008-09-16 | 2009-06-11 | 用于治疗增生性疾病的药物组合物 |
HK10107872.6A HK1141447A1 (en) | 2008-09-16 | 2010-08-18 | Pharmaceutical composition for the treatment of proliferative diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101496507A CN101675930B (zh) | 2008-09-16 | 2008-09-16 | 用于治疗增生性疾病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101675930A CN101675930A (zh) | 2010-03-24 |
CN101675930B true CN101675930B (zh) | 2012-04-25 |
Family
ID=42028743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101496507A Active CN101675930B (zh) | 2008-09-16 | 2008-09-16 | 用于治疗增生性疾病的药物组合物 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101675930B (zh) |
HK (1) | HK1141447A1 (zh) |
WO (1) | WO2010031265A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102271848B1 (ko) * | 2013-11-01 | 2021-07-01 | 피트니 파마슈티컬스 피티와이 리미티드 | 암 치료용 약학적 배합물 |
CN104072412A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 |
CN104086484B (zh) * | 2014-07-08 | 2016-05-25 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用 |
CN105622499A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN105622498A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN105541708A (zh) * | 2014-10-28 | 2016-05-04 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
CN106176757B (zh) * | 2015-05-25 | 2019-12-10 | 江苏恒瑞医药股份有限公司 | 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途 |
CN107669685A (zh) * | 2016-08-02 | 2018-02-09 | 江苏恒瑞医药股份有限公司 | 阿帕替尼与替加氟和紫杉类药物联合用于制备治疗胃癌的药物中的用途 |
TWI764943B (zh) | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
US20210363253A1 (en) | 2017-12-29 | 2021-11-25 | Jiangsu Hengrui Medicine Co., Ltd. | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer |
CN108409647B (zh) * | 2018-03-14 | 2020-03-24 | 盐城师范学院 | 一种阿帕替尼的制备方法 |
CN108524938B (zh) * | 2018-06-15 | 2020-06-19 | 深圳大学 | Cdk6小分子抑制剂在降低肝癌细胞对抗肿瘤药或放疗的耐受性中的应用 |
CN110841607B (zh) * | 2019-11-22 | 2020-07-24 | 中国科学院地质与地球物理研究所 | 一种超低本底金特效树脂及其制备和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1502608A (zh) * | 2002-11-27 | 2004-06-09 | 南京凯衡科贸有限公司 | 具有抑制血管生成活性的六员氨基酰胺类衍生物 |
-
2008
- 2008-09-16 CN CN2008101496507A patent/CN101675930B/zh active Active
-
2009
- 2009-06-11 WO PCT/CN2009/072238 patent/WO2010031265A1/zh active Application Filing
-
2010
- 2010-08-18 HK HK10107872.6A patent/HK1141447A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1502608A (zh) * | 2002-11-27 | 2004-06-09 | 南京凯衡科贸有限公司 | 具有抑制血管生成活性的六员氨基酰胺类衍生物 |
Also Published As
Publication number | Publication date |
---|---|
HK1141447A1 (en) | 2010-11-12 |
CN101675930A (zh) | 2010-03-24 |
WO2010031265A1 (zh) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101675930B (zh) | 用于治疗增生性疾病的药物组合物 | |
CN100384424C (zh) | 协同治疗癌症的方法和组合物 | |
ES2823756T3 (es) | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR | |
JP2014132009A5 (zh) | ||
JP2006503867A (ja) | 癌を処置するための相乗的な方法および組成物 | |
CA2622136A1 (en) | Methods of using saha and erlotinib for treating cancer | |
CN101325955A (zh) | 用saha和培美曲塞治疗癌症的方法 | |
CN101528037A (zh) | 使用saha和硼替佐米治疗多发性骨髓瘤的方法 | |
JP5993573B2 (ja) | 医薬組み合わせ | |
TW201343178A (zh) | 用於治療卵巢癌之組合療法 | |
Collins | Cancer pharmacology | |
JP2021523169A (ja) | ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 | |
US20230226040A1 (en) | Combination therapy comprising an fgfr inhibitor and a kras inhibitor | |
JP2005513167A (ja) | エポシロン誘導体と代謝拮抗剤からなる組合せ | |
JP2020528418A (ja) | BET阻害剤及びBcl−2阻害剤を用いた併用療法 | |
TW201306833A (zh) | 包含康布列塔司他汀(combretastatins)族衍生物及西妥昔單抗(cetuximab)之組合 | |
TWI528960B (zh) | 用於治療增生性疾病的醫藥組合物 | |
CN106176757B (zh) | 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途 | |
Baig | Principles and practice of chemotherapy | |
MXPA06003056A (es) | Tratamiento de tumores estromales gastrointestinales con imatinib y midostaurin. | |
JP6643978B2 (ja) | 頭頚部がんの処置または予防において使用されるpi3キナーゼ阻害剤とパクリタキセルの組合せ | |
Shah et al. | Optimizing high dose melphalan | |
AU2015210337B2 (en) | Pharmaceutical combination | |
TW202313039A (zh) | Pm14用途與方案 | |
Czito et al. | A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1141447 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1141447 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: HENGRUI PHARMACEUTICAL CO., LTD., SHANGHAI Effective date: 20130723 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 222002 LIANYUNGANG, JIANGSU PROVINCE TO: 222047 LIANYUNGANG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130723 Address after: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7 Patentee after: Hengrui Medicine Co., Ltd., Jiangsu Prov. Patentee after: Hengrui Pharmaceutical Co., Ltd., Shanghai Address before: 222002 No. 145, Renmin East Road, Sinpo District, Jiangsu, Lianyungang Patentee before: Hengrui Medicine Co., Ltd., Jiangsu Prov. |